Shield Therapeutics plc (LON:STX – Get Free Report) shot up 10.1% on Thursday . The company traded as high as GBX 5.53 and last traded at GBX 5.45. 2,546,040 shares were traded during trading, an increase of 13% from the average daily volume of 2,251,328 shares. The stock had previously closed at GBX 4.95.
Shield Therapeutics Stock Up 10.1%
The stock has a market capitalization of £58.29 million, a price-to-earnings ratio of -2.73 and a beta of 1.72. The company has a debt-to-equity ratio of -146.28, a current ratio of 0.75 and a quick ratio of 2.16. The business has a fifty day moving average of GBX 5.42 and a 200 day moving average of GBX 7.17.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
- Permian Resources Rally Faces a Test
- Google Cloud Just Gave Rezolve AI a Major Vote of Confidence
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
